We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+6.82%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$671M
AUM Growth
-$749M
Cap. Flow
-$596M
Cap. Flow %
-88.74%
Top 10 Hldgs %
41.79%
Holding
248
New
39
Increased
16
Reduced
53
Closed
62

Top Buys

Rank Stock Value
1
KZR
Kezar Life Sciences
KZR
+$11.5M
2
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$7.64M
3
CLDX icon
Celldex Therapeutics
CLDX
+$6.48M
4
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$5.45M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.08M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$13.7M
2
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$7.89M
3
CMPS
Compass Pathways
CMPS
+$6.85M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$5.93M
5
BCAB icon
BioAtla
BCAB
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 50.73%
2 Consumer Staples 0.3%
3 Technology 0.3%
4 Financials 0.11%
5 Real Estate 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CASI
101
DELISTED
CASI Pharmaceuticals
CASI
$978K 0.15%
122,307
– –
VTGN icon
102
VistaGen Therapeutics
VTGN
$9.89M
$927K 0.14%
15,856
-4,167
-21% -$271K
SLDB icon
103
Solid Biosciences
SLDB
$794M
$911K 0.14%
34,744
– –
CYCN icon
104
Cyclerion Therapeutics
CYCN
$14.9M
$866K 0.13%
25,131
– –
MBIO icon
105
Mustang Bio
MBIO
$4.32M
$840K 0.13%
675
– –
HARP
106
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$840K 0.13%
11,129
– –
NXTC icon
107
NextCure
NXTC
$16.8M
$804K 0.12%
11,171
-31,259
-74% -$2.62M
BDTX icon
108
Black Diamond Therapeutics
BDTX
$96.8M
$801K 0.12%
150,484
– –
DMAC icon
109
DiaMedica Therapeutics
DMAC
$342M
$779K 0.12%
209,082
-101,959
-33% -$400K
ISEE
110
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$778K 0.12%
46,519
-170,000
-79% -$2.79M
QCLS
111
Q/C Technologies Inc
QCLS
$20.5M
$751K 0.11%
+41
New +$927K
AGTC
112
DELISTED
Applied Genetic Technologies Corporation
AGTC
$742K 0.11%
390,394
– –
BLCM
113
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$739K 0.11%
496,756
– –
BLSA
114
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$728K 0.11%
73,789
– –
TENX icon
115
Tenax Therapeutics
TENX
$363M
$722K 0.11%
434
+143
+49% +$322K
VTVT icon
116
vTv Therapeutics
VTVT
$127M
$697K 0.1%
+17,500
New +$940K
KA
117
DELISTED
Kineta, Inc. Common Stock
KA
$678K 0.1%
32,680
– –
HEPA
118
DELISTED
Hepion Pharmaceuticals
HEPA
$630K 0.09%
553
– –
ZLAB icon
119
CALL
Zai Lab
ZLAB
$2.06B
$603K 0.09%
+9,600
New +$814K
PBLA
120
DELISTED
Panbela Therapeutics, Inc. Common Stock
PBLA
$592K 0.09%
14
– –
CRBP icon
121
Corbus Pharmaceuticals
CRBP
$166M
$584K 0.09%
31,618
– –
ICPT
122
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$562K 0.08%
34,565
– –
CDAK
123
DELISTED
Codiak BioSciences, Inc. Common Stock
CDAK
$554K 0.08%
49,680
-70,215
-59% -$973K
CYTO
124
DELISTED
Altamira Therapeutics Ltd
CYTO
$553K 0.08%
762
-236
-24% -$158K
FATE icon
125
Fate Therapeutics
FATE
$286M
$528K 0.08%
+9,038
New +$512K
3 4
5
6 7

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2021 Portfolio in Review

As of Q4 2021, Ikarian Capital held 248 positions worth $671M, down 53% from $1.42B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Ikarian Capital withdrew a net $596M in Q4 2021, closing 62 positions and reducing 53 holdings. Its most notable exit was Apellis Pharmaceuticals, an estimated $13.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 51% of assets, up from 30% a quarter earlier, followed by Consumer Staples and Technology.

Against the trend, Ikarian Capital opened a new position in Kezar Life Sciences worth $17.1M.

  • Ikarian Capital's largest Q4 2021 buy was Kezar Life Sciences: 102,092 shares worth $17.1M.
  • Ikarian Capital added most to Zentalis Pharmaceuticals in Q4 2021, an estimated $7.64M increase.
  • Ikarian Capital's biggest Q4 2021 reduction was Xenon Pharmaceuticals, cutting an estimated $5.93M.
  • Ikarian Capital fully exited Apellis Pharmaceuticals in Q4 2021, selling an estimated $13.7M.
  • Ikarian Capital's ten largest holdings make up 42% of its $671M portfolio in Q4 2021.
  • Ikarian Capital opened 39 new positions and closed 62 in Q4 2021.
  • Ikarian Capital's portfolio value fell 53% quarter-over-quarter to $671M.

Based on Ikarian Capital's 13F filing for Q4 2021, filed 14 Feb 2022.